UVB-induced mutations in human key gatekeeper genes governing signalling pathways and consequences for skin tumourigenesis

Photochemical and Photobiological Sciences

Volumn 2, Issue 8, 2003, Pages 825-834

  Ehrhart, Jean Claude ^a,b   Gosselet, Fabien P ^a   Culerrier, Raphaël M ^a   Sarasin, Alain ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN; PROTEIN; PROTEIN P14ARF; PROTEIN P16INK4A; PROTEIN P53; PROTEIN PATCHED 1; SMAD PROTEIN; SMO PROTEIN; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; SHH PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

BASAL CELL CARCINOMA; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; GENE MUTATION; HUMAN; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET B RADIATION; XERODERMA PIGMENTOSUM; COCARCINOGENESIS; CYTOLOGY; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY; RADIATION EXPOSURE; RADIATION INJURY; SKIN TUMOR; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION;

ERINACEIDAE; PYRONIA TITHONUS;

COCARCINOGENESIS; DNA REPAIR; GENES, TUMOR SUPPRESSOR; HEDGEHOG PROTEINS; HUMANS; KERATINOCYTES; MUTATION; NEOPLASMS, RADIATION-INDUCED; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS; ULTRAVIOLET RAYS;

EID: 0642347221     PISSN: 1474905X     EISSN: 14749092     Source Type: Journal    
DOI: 10.1039/b302281a     Document Type: Review

References (82)

1. K. W. Kinzler and B. Vogelstein, Cancer-susceptibility genes. Gatekeepers and caretakers, Nature, 1997, 386, 761 and 763.
2. A. Sarasin, The molecular pathways of ultraviolet-induced carcinogenesis, Mutat. Res., 1999, 428, 5-10.
3. A. Stary and A. Sarasin, The genetics of the hereditary xeroderma pigmentosum syndrome, Biochimie, 2002, 84, 49-60.
4. D. Tomescu, G. Kavanagh, T. Ha, H. Campbell and D. W. Melton, Nucleotide excision repair gene XPD polymorphisms and genetic predisposition to melanoma, Carcinogenesis, 2001, 22, 403-408.
5. U. Vogel, M. Hedayati, M. Dybdahl, L. Grossman and B. A. Nexo, Polymorphisms of the DNA repair gene XPD: correlations with risk of basal cell carcinoma revisited, Carcinogenesis, 2001, 22, 899-904.
6. S. L. Winsey, N. A. Haldar, H. P. Marsh, M. Bunce, S. E. Marshall, A. L. Harris, F. Wojnarowska and K. I. Welsh, A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer, Cancer Res., 2000, 60, 5612-5616.
7. L. Daya-Grosjean and A. Sarasin, UV-specific mutations of the human patched gene in basal cell carcinomas from normal individuals and xeroderma piementosum patients, Mutat. Res., 2000, 450, 193-199.
8. R. J. Gorlin, Nevoid basal cell carcinoma syndrome, Dermatol. Clin., 1995, 13, 113-125.
9. D. Sidransky, Is human patched the gatekeeper of common skin cancers?, Nat. Genet., 1996, 14, 7-8.
10. W. Vermeulen, A. J. van Vuuren, M. Chipoulet, L. Schaeffer, E. Appeldoorn, G. Weeda, N. G. Jaspers, A. Priestley, C. F. Arlett, A. R. Lehmann, M. Stefanini, M. Mezzina, A. Sarasin, D. Bootsma, J.-M. Egly and J. H. J. Hoeijmakers, Three unusual repair deficiencies associated with transcription factor BTF2(TFIIH): evidence for the existence of a transcription syndrome, Cold Spring Harbor Symp. Quant. Biol., 1994, 59, 317-329.
11. D. Perdiz, P. Grof, M. Mezzina, O. Nikaido, E. Moustacchi and E. Sage, Distribution and repair of bipyrimidine photoproducts in solar UV-irradiated mammalian cells. Possible role of Dewar photoproducts in solar mutagenesis, J. Biol. Chem., 2000, 275, 26732-26742.
12. J. L. Ravanat, T. Douki and J. Cadet, Direct and indirect effects of UV radiation on DNA and its components, J. Photochem. Photobiol. B, 2001, 63, 88-102.
13. P. C. Hanawalt, Subpathways of nucleotide excision repair and their regulation, Oncogene, 2002, 21, 8949-8956.
14. J. E. Cleaver, Xeroderma pigmentosum: the first of the cellular caretakers, Trends. Biochem. Sci., 2001, 26, 398-401.
15. M. Classon and E. Harlow, The retinoblastoma tumour suppressor in development and cancer, Nat. Rev. Cancer, 2002, 2, 910-917.
16. C. Lee, J. H. Chang, H. S. Lee and Y. Cho, Structural basis for the recognition of the E2F transactivation domain by the retinoblastoma tumor suppressor, Genes Dev., 2002, 16, 3199-3212.
17. N. U. Ahmed, M. Ueda and M. Ichihashi, Induced expression of p16 and p21 proteins in UVB-irradiated human epidermis and cultured keratinocytes, J. Dermatol. Sci., 1999, 19, 175-181.
18. M. Chazal, C. Marionnet, L. Michel, K. Mollier, J. E. Dazard, V. Della Valle, C. J. Larsen, M. P. Gras and N. Basset-Seguin, P16(INK4A) is implicated in both the immediate and adaptative response of human keratinocytes to UVB irradiation, Oncogene, 2002, 21, 2652-2661.
19. S. Pavey, S. Conroy, T. Russell and B. Gabrielli, Ultraviolet radiation induces p16CDKN2A expression in human skin, Cancer Res., 1999, 59, 4185-4189.
20. M. Piepkorn, The expression of p16(INK4a), the product of a tumor suppressor gene for melanoma, is upregulated in human melanocytes by UVB irradiation, J. Am. Acad. Dermatol., 2000, 42, 741-745.
21. D. T. Bishop, F. Demenais, A. M. Goldstein, W. Bergman, J. N. Bishop, B. Bressac-de Paillerets, A. Chompret, P. Ghiorzo, N. Gruis, J. Hansson, M. Harland, N. Hayward, E. A. Holland, G. J. Mann, M. Mantelli, D. Nancarrow, A. Platz and M. A. Tucker, Geographical variation in the penetrance of CDKN2A mutations for melanoma, J. Natl. Cancer, Inst., 2002, 94, 894-903.
22. B. Bressac-de-Paillerets, M. F. Avril, A. Chompret and F. Demenais, Genetic and environmental factors in cutaneous malignant melanoma. Biochimie, 2002, 84, 67-74.
23. N. Soufir and N. Basset-Seguin, [The INK4a-ARF locus: role in the genetic predisposition to familial melanoma and in skin carcinogenesis], Bull. Cancer, 2001, 88, 1061-1067.
24. N. Soufir, M. Ribojad, T. Magnaldo, O. Thibaudeau, G. Delestaing, L. Daya-Grosjean, J. Rivet, A. Sarasin and N. Basset-Seguin, Germline and somatic mutations of the INK4a-ARF gene in a xeroderma pismentosum group C patient, J. Invest. Dermatol., 2002, 119, 1355-1360.
25. N. E. Sharpless and R. A. DePinho, The INK4A/ARF locus and its two gene products, Curr. Opin. Genet. Dev., 1999, 9, 22-30.
26. D. Polsky, K. Melzer, C. Hazan, K. S. Panageas, K. Busam, M. Drobnjak, H. Kamino, J. G. Spira, A. W. Kopf, A. Houghton, C. Cordon-Cardo and I. Osman, HDM2 protein overexpression and prognosis in primary malignant melanoma, J. Natl. Cancer Inst., 2002, 94, 1803-1806.
27. M. Ruas and G. Peters, The p16INK4a/CDKN2A tumor suppressor and its relatives, Biochim. Biophys. Acta, 1998, 1378, F115-177.
28. D. Polsky, A. Z. Young, K. J. Busam and R. M. Alani, The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas, Cancer Res., 2001, 61, 6008-6011.
29. N. Soufir, L. Daya-Grosjean, P. de La Salmoniere, J. P. Moles, L. Dubertret, A. Sarasin and N. Basset-Seguin, Association between INK4a-ARF and p53 mutations in skin carcinomas of xeroderma pigmentosum patients, J. Natl. Cancer Inst., 2000, 92, 1841-1847.
30. Y. Haupt, A. I. Robles, C. Prives and V. Rotter, Deconstruction of p53 functions and regulation, Oncogene, 2002, 21, 8223-8231.
31. L. Daya-Grosjean, C. Robert, C. Drougard, H. Suarez and A. Sarasin, High mutation frequency in ras genes of skin tumors isolated from DNA repair deficient xeroderma pigmentosum patients, Cancer Res., 1993, 53, 1625-1629.
32. P. A. Clark, S. Llanos and G. Peters, Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2, Oncogene, 2002, 21, 4498-1507.
33. A. Datta, A. Nag and P. Raychaudhuri, Differential regulation of E2F1, DP1, and the E2F1/DP1 complex by ARF, Mol. Cell. Biol., 2002, 22, 8398-8408.
34. T. Buschmann, S. Y. Fuchs, C. G. Lee, Z. Q. Pan and Z. Ronai, SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53, Cell, 2000, 101, 753-762.
35. F. J. Stott, S. Bates, M. C. James, B. B. McConnell, M. Starborg, S. Brookes, I. Palmero, K. Ryan, E. Hara, K. H. Vousden and G. Peters, The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2, EMBO J., 1998, 17, 5001-5014.
36. H. Rizos, S. Puig, C. Badenas, J. Malvehy, A. P. Darmanian, L. Jimenez, M. Mila and R. F. Kefford, A melanoma-associated germline mutation in exon 1beta inactivates p14ARF, Oncogene, 2001, 20, 5543-5547.
37. R. Dobrowolski, R. Hein, R. Buettner and A. K. Bosserhoff, Loss of p14ARF expression in melanoma, Arch. Dermatol. Res., 2002, 293, 545-551.
38. G. Ling, A. Ahmadian, A. Persson, A. B. Unden, G. Afink, C. Williams, M. Uhlen, R. Toftgard, J. Lundeberg and F. Ponten, PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer, Oncogene, 2001, 20, 7770-7778.
39. G. Giglia, N. Dumaz, C. Drougard, M. F. Avril, L. Daya-Grosjean and A. Sarasin, p53 mutations in skin and internal tumors of xeroderma pigmentosum patients belonging to the complementation group C, Cancer Res., 1998, 58, 4402-4409.
40. A. Spatz, G. Giglia-Mari, S. Benhamou and A. Sarasin, Association between DNA repair-deficiency and high level of p53 mutations in melanoma of Xeroderma pigmentosum, Cancer Res., 2001, 61, 2480-2486.
41. A. Ruiz i Altaba, P. Sanchez and N. Dahmane, Gli and hedgehog in cancer: tumours, embryos and stem cells, Nat. Rev. Cancer, 2002, 2, 361-372.
42. A. E. Bale and K. P. Yu, The hedgehog pathway and basal cell carcinomas, Hum. Mol. Genet., 2001, 10, 757-762.
43. J. Taipale, M. K. Cooper, T. Maiti and P. A. Beachy, Patched acts catalytically to suppress the activity of Smoothened, Nature, 2002, 418, 892-896.
44. G. Regl, G. W. Neill, T. Eichberger, M. Kasper, M. S. Ikram, J. Koller, H. Hintner, A. G. Quinn, A. M. Frischauf and F. Aberger, Human GLI2 and GLI1 are part of a positive feedback mechanism in Basal Cell Carcinoma, Oncogene, 2002, 21, 5529-5539.
45. J. W. Yoon, Y. Kita, D. J. Frank, R. R. Majewski, B. A. Konicek, M. A. Nobrega, H. Jacob, D. Walterhouse and P. Iannaccone, Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation, J. Biol. Chem., 2002, 277, 5548-5555.
46. M. T. Teh, S. T. Wong, G. W. Neill, L. R. Ghali, M. P. Philpott and A. G. Quinn, FOXM1 is a downstream target of Gli1 in basal cell carcinomas, Cancer Res., 2002, 62, 4773-4780.
47. H. Fan, A. E. Oro, M. P. Scott and P. A. Khavari, Induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog, Nat. Med., 1997, 3, 788-792.
48. I. D. Louro, E. C. Bailey, X. Li, L. S. South, P. R. McKie-Bell, B. K. Yoder, C. C. Huang, M. R. Johnson, A. E. Hill, R. L. Johnson and J. M. Ruppert, Comparative gene expression profile analysis of GLI and c-MYC in an epithelial model of malignant transformation. Cancer Res., 2002, 62, 5867-5873.
49. A. Pizarro, N. Benito, P. Navarro, J. Palacios, A. Cano, M. Quintanilla, F. Contreras and C. Gamallo, E-cadherin expression in basal cell carcinoma, Br. J. Cancer, 1994, 69, 157-162.
50. E. A. Barnes, M. Kong, V. Ollendorff and D. J. Donoghue, Patched1 interacts with cyclin B1 to regulate cell cycle progression, EMBO J., 2001, 20, 2214-2223.
51. J. Taipale and P. A. Beachy, The Hedgehog and Wnt signalling pathways in cancer, Nature, 2001, 411, 349-354.
52. M. Aszterbaum, A. Rothman, R. L. Johnson, M. Fisher, J. Xie, J. M. Bonifas, X. Zhang, M. P. Scott and E. H. Epstein Jr., Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome, J. Invest. Dermatol., 1998, 110, 885-888.
53. A. Ziegler, A. Jonason, J. Simon, D. Leffell and D. E. Brash, Tumor suppressor gene mutations and photocarcinogenesis, Photochem. Photobiol., 1996, 63, 432-435.
54. J. M. Bonifas, S. Pennypacker, P. T. Chuang, A. P. McMahon, M. Williams, A. Rosenthal, F. J. De Sauvage and E. H. Epstein Jr., Activation of expression of hedgehog target genes in basal cell carcinomas, J. Invest. Dermatol., 2001, 116, 739-742.
55. N. Bodak, S. Queille, M. F. Avril, B. Bouadjar, C. Drougard, A. Sarasin and L. Daya-Grosjean, High levels of patched gene mutations in basal-cell carcinomas from patients with xeroderma pigmentosum, Proc. Natl. Acad. Sci. USA, 1999, 96, 5117-5122.
56. M. D'Errico, A. Calcagnile, F. Canzona, B. Didona, P. Posteraro, R. Cavalieri, R. Corona, I. Vorechovsky, T. Nardo, M. Stefanini and E. Dogliotti, UV mutation signature in tumor suppressor genes involved in skin carcinogenesis in xeroderma pigmentosum patients, Oncogene, 2000, 19, 463-467.
57. S. Couve-Privat, B. Bouadjar, M. F. Avril, A. Sarasin and L. Daya-Grosjean, Significantly high levels of ultraviolet-specific mutations in the smoothened gene in basal cell carcinomas from DNA repair-deficient xeroderma pigmentosum patients, Cancer Res., 2002, 62, 7186-7189.
58. J. L. Mullor, N. Dahmane, T. Sun and A. Ruiz i Altaba, Wnt signals are targets and mediators of Gli function, Curr. Biol., 2001, 11, 769-773.
59. V. M. Braga, M. Betson, X. Li and N. Lamarche-Vane, Activation of the small GTPase Rac is sufficient to disrupt cadherin-dependent cell-cell adhesion in normal human keratinocytes, Mol. Biol. Cell., 2000, 11, 3703-3721.
60. A. J. Zhu and F. M. Watt, beta-catenin signalling modulates proliferative potential of human epidermal keratinocytes independently of intercellular adhesion, Development., 1999, 126, 2285-2298.
61. H. Tsuji, A. Ishida-Yamamoto, H. Takahashi and H. Iizuka, Nuclear localization of beta-catenin in the hair matrix cells and differentiated keratinocytes, J. Dermatol. Sci., 2001, 27, 170-177.
62. J. Huelsken and W. Birchmeier, New aspects of Wnt signaling pathways in higher vertebrates, Curr. Opin. Genet. Der., 2001, 11, 547-553.
63. R. T. Moon, B. Bowerman, M. Boutros and N. Perrimon, The promise and perils of Wnt signaling through beta-catenin, Science, 2002, 296, 1644-1646.
64. M. Peifer and P. Polakis, Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus, Science, 2000, 287, 1606-1609.
65. T. C. He, A. B. Sparks, C. Rago, H. Hermeking, L. Zawel, L. T. da Costa, P. J. Morin, B. Vogelstein and K. W. Kinzler, Identification of c-MYC as a target of the APC pathway, Science, 1998, 281, 1509-1512.
66. M. Shtutman, J. Zhurinsky, I. Simcha, C. Albanese, M. D'Amico, R. Pestell and A. Ben-Ze'ev, The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway, Proc. Natl. Acad. Sci. USA, 1999, 96, 5522-5527.
67. Q. Tang, M. Gonzales, H. Inoue and G. T. Bowden, Roles of Akt and glycogen synthase kinase 3beta in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes, Cancer Res., 2001, 61, 4329-4332.
68. T. A. Chan, Z. Wang, L. H. Dang, B. Vogelstein and K. W. Kinzler, Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation, Proc. Natl. Acad. Sci. USA 2002, 99, 8265-8270.
69. F. Yamazaki, Y. Aragane, A. Kawada and T. Tezuka, Immunohistochemical detection for nuclear beta-catenin in sporadic basal cell carcinoma, Br. J. Dermatol., 2001, 145, 771-777.
70. E. F. Chan, U. Gat, J. M. McNiff and E. Fuchs, A common human skin tumour is caused by activating mutations in beta-catenin, Nat. Genet., 1999, 21, 410-413.
71. J. Reifenberger, C. B. Knobbe, M. Wolter, B. Blaschke, K. W. Schulte, T. Pietsch, T. Ruzicka and G. Reifenberger, Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC, Int. J. Cancer, 2002, 100, 549-556.
72. C. Eng, To be or not to BMP, Nat. Genet., 2001, 28, 105-107.
73. E. A. Hwang, H. B. Lee and K. C. Tark, Comparison of bone morphogenetic protein receptors expression in the fetal and adult skin, Yonsei. Med. J., 2001, 42, 581-586.
74. B. Y. Qin, B. M. Chacko, S. S. Lam, M. P. de Caestecker, J. J. Correia and K. Lin, Structural basis of Smad1 activation by receptor kinase phosphorylation, Mol. Cell., 2001, 8, 1303-1312.
75. J. S. Kim, H. Crooks, T. Dracheva, T. G. Nishanian, B. Singh, J. Jen and T. Waldman, Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Res., 2002, 62, 2744-2748.
76. S Kawai and T. Sugiura, Characterization of human bone morphogenetic protein (BMP)-4 and -7 gene promoters: activation of BMP promoters by Gli, a sonic hedgehog mediator, Bone, 2001, 29, 54-61.
77. C. Niemann and F. M. Watt, Designer skin: lineage commitment in postnatal epidermis, Trends Cell. Biol., 2002, 12, 185-192.
78. A. S. Jonason, S. Kunala, G. J. Price, R. J. Restifo, H. M. Spinelli, J. A. Persing, D. J. Lefell, R. E. Tarone and D. E. Brash, Frequent clones of p53-mutated keratinocytes in normal human skin, Proc. Natl. Acad. Sci. USA, 1996, 93, 14025-14029.
79. D. E. Brash, A. Ziegler, A. S. Jonason, J. A. Simon, S. Kunala and D. J. Leffell, Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion, J. Investig. Dermatol. Symp. Proc., 1996, 1, 136-142.
80. Z. P. Ren, A. Hedrum, F. Ponten, M. Nister, A. Ahmadian, J. Lundeberg, M. Uhlen and J. Ponten, Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes, Oncogene, 1996, 12, 765-773.
81. D. E. Brash and J. Ponten, Skin precancer, Cancer Surv., 1998, 32, 69-113.
82. D. Hanahan and R. A. Weinberg, The hallmarks of cancer, Cell, 2000, 100, 57-70.